Systemic primary carnitine deficiency induces severe arrhythmia due to shortening of QT interval.

Cardiomyopathy Primary carnitine deficiency Short QT syndrome Sudden death Ventricular arrythmia

Journal

Molecular genetics and metabolism
ISSN: 1096-7206
Titre abrégé: Mol Genet Metab
Pays: United States
ID NLM: 9805456

Informations de publication

Date de publication:
Dec 2023
Historique:
received: 05 06 2023
revised: 07 11 2023
accepted: 08 11 2023
pubmed: 19 11 2023
medline: 19 11 2023
entrez: 18 11 2023
Statut: ppublish

Résumé

Systemic primary carnitine deficiency (PCD) is characterized by cardiomyopathy and arrhythmia. Without carnitine supplementation, progression is usually towards fatal cardiac decompensation. While the cardiomyopathy is most likely secondary to energy deficiency, the mechanism of arrhythmia is unclear, and may be related to a short QT interval. We aim to describe rhythmic manifestations at diagnosis and with carnitine supplementation. French patients diagnosed for PCD were retrospectively included. Clinical and para clinical data at diagnosis and during follow-up were collected. Electrocardiograms with QT interval measurements were blinded reviewed by two paediatric cardiologists. Nineteen patients (median age at diagnosis 2.3 years (extremes 0.3-28.9)) followed in 8 French centres were included. At diagnosis, 21% of patients (4/19) had arrhythmia (2 ventricular fibrillations, 1 ventricular tachycardia and 1 sudden death), and 84% (16/19) had cardiomyopathy. Six electrocardiograms before treatment out of 11 available displayed a short QT (QTc < 340 ms). Median corrected QTc after carnitine supplementation was 404 ms (extremes 341-447) versus 350 ms (extremes 282-421) before treatment (p < 0.001). The whole QTc was prolonged, and no patient reached the criterion of short QT syndrome with carnitine supplementation. Three patients died, probably from rhythmic cause without carnitine supplementation (two extra-hospital sudden deaths and one non-recoverable rhythmic storm before carnitine supplementation), whereas no rhythmic complication occurred in patients with carnitine supplementation. PCD is associated with shortening of the QT interval inducing severe arrhythmia. A potential explanation would be a toxic effect of accumulated fatty acid and metabolites on ionic channels embedded in the cell membrane. Carnitine supplementation normalizes the QTc and prevents arrhythmia. Newborn screening of primary carnitine deficiency would prevent avoidable deaths.

Sections du résumé

BACKGROUND BACKGROUND
Systemic primary carnitine deficiency (PCD) is characterized by cardiomyopathy and arrhythmia. Without carnitine supplementation, progression is usually towards fatal cardiac decompensation. While the cardiomyopathy is most likely secondary to energy deficiency, the mechanism of arrhythmia is unclear, and may be related to a short QT interval.
OBJECTIVE OBJECTIVE
We aim to describe rhythmic manifestations at diagnosis and with carnitine supplementation.
METHODS METHODS
French patients diagnosed for PCD were retrospectively included. Clinical and para clinical data at diagnosis and during follow-up were collected. Electrocardiograms with QT interval measurements were blinded reviewed by two paediatric cardiologists.
RESULTS RESULTS
Nineteen patients (median age at diagnosis 2.3 years (extremes 0.3-28.9)) followed in 8 French centres were included. At diagnosis, 21% of patients (4/19) had arrhythmia (2 ventricular fibrillations, 1 ventricular tachycardia and 1 sudden death), and 84% (16/19) had cardiomyopathy. Six electrocardiograms before treatment out of 11 available displayed a short QT (QTc < 340 ms). Median corrected QTc after carnitine supplementation was 404 ms (extremes 341-447) versus 350 ms (extremes 282-421) before treatment (p < 0.001). The whole QTc was prolonged, and no patient reached the criterion of short QT syndrome with carnitine supplementation. Three patients died, probably from rhythmic cause without carnitine supplementation (two extra-hospital sudden deaths and one non-recoverable rhythmic storm before carnitine supplementation), whereas no rhythmic complication occurred in patients with carnitine supplementation.
CONCLUSION CONCLUSIONS
PCD is associated with shortening of the QT interval inducing severe arrhythmia. A potential explanation would be a toxic effect of accumulated fatty acid and metabolites on ionic channels embedded in the cell membrane. Carnitine supplementation normalizes the QTc and prevents arrhythmia. Newborn screening of primary carnitine deficiency would prevent avoidable deaths.

Identifiants

pubmed: 37979236
pii: S1096-7192(23)00363-3
doi: 10.1016/j.ymgme.2023.107733
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

107733

Informations de copyright

Copyright © 2023. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of Competing Interest None.

Auteurs

Pierre Lodewyckx (P)

Institut des Cardiopathies Congénitales de Tours and FHU PRECICARE, CHU Tours, Tours, France.

Jean Issa (J)

Institut des Cardiopathies Congénitales de Tours and FHU PRECICARE, CHU Tours, Tours, France.

Margaux Gaschignard (M)

CCMR Maladies Métaboliques, CHU Bordeaux, Bordeaux, France.

Delphine Lamireau (D)

CCMR Maladies Métaboliques, CHU Bordeaux, Bordeaux, France.

Pascale De Lonlay (P)

Maladie métabolique, Hôpital Necker Enfant Malade, APHP, Université Paris Cité, Filière G2M, MetabERN, Paris, France.

Aude Servais (A)

Maladie métabolique, Hôpital Necker Enfant Malade, APHP, Université Paris Cité, Filière G2M, MetabERN, Paris, France.

Magalie Barth (M)

Maladie métabolique, CHU Angers, Angers, France.

Sandy Courapied (S)

Maladie métabolique, CHU Lille, Filière G2M, MetabERN, Lille, France.

Gilles Morin (G)

Maladie métabolique, CHU Amiens, Amiens, France.

Nadir Benbrik (N)

Fédération cardiologie pédiatrique, CHU Nantes, Nantes, France.

François Maillot (F)

CRMR Maladies Héréditaires du Métabolisme ToTeM, CHU Tours, Tours, France.

Dominique Babuty (D)

Cardiologie, CHU Tours, Tours, France.

François Labarthe (F)

CRMR Maladies Héréditaires du Métabolisme ToTeM, CHU Tours, Tours, France; INSERM UMR 1069, Université de Tours, Tours, France.

Bruno Lefort (B)

Institut des Cardiopathies Congénitales de Tours and FHU PRECICARE, CHU Tours, Tours, France; INSERM UMR 1069, Université de Tours, Tours, France. Electronic address: lefort81@gmail.com.

Classifications MeSH